###begin article-title 0
The Death Receptor 3-TNF-like protein 1A pathway drives adverse bone pathology in inflammatory arthritis
###end article-title 0
###begin p 1
###xml 38 53 38 53 <email xmlns:xlink="http://www.w3.org/1999/xlink">WangEC@cf.ac.uk</email>
CORRESPONDENCE Eddie Chung Yern Wang: WangEC@cf.ac.uk
###end p 1
###begin p 2
This article is distributed under the terms of an Attribution-Noncommercial-Share Alike-No Mirror Sites license for the first six months after the publication date (see ). After six months it is available under a Creative Commons License (Attribution-Noncommercial-Share Alike 3.0 Unported license, as described at ).
###end p 2
###begin p 3
###xml 427 429 427 429 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ko</sup>
###xml 856 858 856 858 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ko</sup>
###xml 430 434 <span type="species:ncbi:10090">mice</span>
###xml 859 863 <span type="species:ncbi:10090">mice</span>
###xml 970 975 <span type="species:ncbi:10090">mouse</span>
###xml 980 983 <span type="species:ncbi:9606">man</span>
###xml 1190 1196 <span type="species:ncbi:10090">murine</span>
Rheumatoid arthritis (RA) is a chronic inflammatory disease of synovial joints that is associated with cartilage and bone destruction. Death Receptor 3 (DR3), a tumor necrosis factor (TNF) receptor superfamily member, has recently been associated with the pathogenesis of RA. We demonstrate that absence of DR3 confers resistance to the development of adverse bone pathology in experimental antigen-induced arthritis (AIA). DR3ko mice exhibited a reduction in all histopathological hallmarks of AIA but, in particular, failed to develop subchondral bone erosions and were completely protected from this characteristic of AIA. In contrast, TNF-like protein 1A (TL1A), the ligand for DR3, exacerbated disease in a dose- and DR3-dependent fashion. Analysis of osteoclast number within AIA joint revealed a reduction in areas susceptible to bone erosion in DR3ko mice, whereas in vitro osteoclastogenesis assays showed that TL1A could directly promote osteoclastogenesis in mouse and man. Treatment with antagonistic anti-TL1A mAb protected animals in a systemic model of RA disease collagen-induced arthritis. We therefore conclude that the DR3-TL1A pathway regulates joint destruction in two murine models of arthritis and represents a potential novel target for therapeutic intervention in inflammatory joint disease.
###end p 3
###begin p 4
M.J. Bull and A.S. Williams contributed equally to this paper.
###end p 4
###begin p 5
###xml 112 113 100 101 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib1">1</xref>
###xml 562 563 546 547 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib2">2</xref>
###xml 564 565 548 549 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib4">4</xref>
###xml 782 783 766 767 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib5">5</xref>
Rheumatoid arthritis (RA) is a chronic inflammatory disease affecting approximately1% of the global population (1). RA is characterized by infiltration of synovial joints by immune cells, principally macrophages, T cells, plasma cells, and hyperplasia of the synovial lining. This eventually results in the destructive phase of disease causing damage to cartilage and bone. It is widely accepted that cytokines and their receptors play a central role in the pathogenesis of RA, thus TNFalpha, IL-1, and IL-6 have been identified as key mediators of the disease (2-4). The role played by members of the TNF receptor superfamily (TNFRSF) in pathological bone resorption has also become widely accepted, with RANK and RANKL acting as crucial factors in differentiation of osteoclasts (5), the primary cell type involved in bone degradation.
###end p 5
###begin p 6
###xml 107 108 107 108 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib6">6</xref>
###xml 295 296 291 292 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib7">7</xref>
###xml 297 298 293 294 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib9">9</xref>
###xml 464 466 460 462 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib10">10</xref>
###xml 493 495 489 491 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib11">11</xref>
###xml 496 498 492 494 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib13">13</xref>
###xml 523 525 519 521 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib14">14</xref>
###xml 616 618 612 614 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib15">15</xref>
###xml 620 622 616 618 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib16">16</xref>
###xml 645 647 641 643 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib17">17</xref>
###xml 732 734 728 730 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib18">18</xref>
###xml 847 849 843 845 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib19">19</xref>
###xml 864 865 860 861 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 999 1001 995 997 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib20">20</xref>
###xml 814 822 <span type="species:ncbi:9606">patients</span>
###xml 989 997 <span type="species:ncbi:9606">patients</span>
DR3 (TRAMP, LARD, Apo3, Wsl1, and TNFRSF25) is a member of the TNFRSF and shows closest homology to TNFR1 (6). Like TNFR1, DR3 contains four extracellular cysteine-rich repeats and is capable of signaling both apoptosis via caspase 8 activation and cell survival via the activation of NFkappaB (7-9). The biological function of DR3 is an area of growing interest. In the immune system, DR3 has been shown to affect negative selection during thymocyte development (10) and can modulate T cell (11-13) and NKT cell function (14). It has also been associated with inflammatory diseases such as irritable bowel disease (15, 16) and atherosclerosis (17). Interestingly, DR3, along with its only known ligand, TNF-like protein 1A (TL1A) (18), has been linked with RA. Duplication of the DR3 gene is more prevalent in RA patients compared with controls (19), whereas TL1A+ mononuclear phagocytes have been identified in rheumatoid synovium and soluble TL1A has been detected in synovial fluid of patients (20). However, functional analysis of the in vivo role of the DR3-TL1A pathway in RA has not yet been reported.
###end p 6
###begin p 7
###xml 65 67 65 67 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ko</sup>
###xml 94 96 94 96 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib10">10</xref>
###xml 422 424 422 424 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib21">21</xref>
###xml 35 39 <span type="species:ncbi:10090">mice</span>
To address this, we have generated mice lacking the DR3 gene (DR3ko) on a C57BL/6 background (10) and used a salient model of experimental arthritis to elucidate functional aspects of DR3 activity. Antigen-induced arthritis (AIA) is a local model of disease which displays many pathological features of RA including cellular infiltration, synovial hyperplasia, pannus formation, cartilage depletion, and bone destruction (21). We show that DR3 is essential for the development of adverse joint pathology in AIA and that anti-TL1A treatment can protect from the systemic model of disease, collagen-induced arthritis (CIA). These results imply an important in vivo function for DR3 in the pathogenesis of inflammatory arthritis and provide proof of principle that countering this pathway may represent a novel therapy for RA.
###end p 7
###begin title 8
RESULTS AND DISCUSSION
###end title 8
###begin title 9
###xml 3 5 3 5 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ko</sup>
###xml 70 72 70 72 <sup xmlns:xlink="http://www.w3.org/1999/xlink">wt</sup>
###xml 6 10 <span type="species:ncbi:10090">mice</span>
DR3ko mice show reduced inflammatory response to AIA compared with DR3wt controls
###end title 9
###begin p 10
###xml 87 89 87 89 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ko</sup>
###xml 102 104 102 104 <sup xmlns:xlink="http://www.w3.org/1999/xlink">wt</sup>
###xml 231 233 231 233 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ko</sup>
###xml 241 243 241 243 <sup xmlns:xlink="http://www.w3.org/1999/xlink">wt</sup>
###xml 382 384 382 384 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ko</sup>
###xml 392 394 392 394 <sup xmlns:xlink="http://www.w3.org/1999/xlink">wt</sup>
###xml 523 531 523 531 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1 A</xref>
###xml 90 94 <span type="species:ncbi:10090">mice</span>
###xml 119 123 <span type="species:ncbi:10090">mice</span>
###xml 244 248 <span type="species:ncbi:10090">mice</span>
###xml 395 399 <span type="species:ncbi:10090">mice</span>
To investigate the in vivo role of DR3 in inflammatory arthritis, we induced AIA in DR3ko mice and DR3wt controls. All mice developed an inflammatory reaction in response to intraarticular injection of methylated BSA, with both DR3ko and DR3wt mice exhibiting a similar pattern of joint swelling over a 21-d time course. Comparable knee joint swelling measurements were noted in DR3ko and DR3wt mice at the peak of response, 1 d after mBSA injection. Thereafter, swelling resolved in both but faster in the absence of DR3 (Fig. 1 A).
###end p 10
###begin p 11
###xml 29 31 29 31 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ko</sup>
###xml 0 37 0 37 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Protection against AIA in DR3<sup>ko</sup> mice.</bold>
###xml 124 125 122 123 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 133 135 131 133 <sup xmlns:xlink="http://www.w3.org/1999/xlink">wt</sup>
###xml 156 158 144 146 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ko</sup>
###xml 353 355 315 317 <sup xmlns:xlink="http://www.w3.org/1999/xlink">wt</sup>
###xml 367 369 329 331 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ko</sup>
###xml 418 420 380 382 <sup xmlns:xlink="http://www.w3.org/1999/xlink">wt</sup>
###xml 432 434 394 396 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ko</sup>
###xml 665 667 626 628 <sup xmlns:xlink="http://www.w3.org/1999/xlink">wt</sup>
###xml 675 677 636 638 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ko</sup>
###xml 805 807 766 768 <sup xmlns:xlink="http://www.w3.org/1999/xlink">wt</sup>
###xml 819 821 780 782 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ko</sup>
###xml 1018 1020 978 980 <sup xmlns:xlink="http://www.w3.org/1999/xlink">wt</sup>
###xml 1028 1030 988 990 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ko</sup>
###xml 1108 1110 1068 1070 <sup xmlns:xlink="http://www.w3.org/1999/xlink">wt</sup>
###xml 1131 1133 1081 1083 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ko</sup>
###xml 32 36 <span type="species:ncbi:10090">mice</span>
###xml 189 193 <span type="species:ncbi:10090">mice</span>
###xml 374 378 <span type="species:ncbi:10090">mice</span>
###xml 439 443 <span type="species:ncbi:10090">mice</span>
###xml 678 682 <span type="species:ncbi:10090">mice</span>
###xml 826 830 <span type="species:ncbi:10090">mice</span>
###xml 1031 1035 <span type="species:ncbi:10090">mice</span>
Protection against AIA in DR3ko mice. (A) Joint swelling after intraarticular injection of mBSA. Data are mean +/- SEM from n = 6 DR3wt (triangle up) or DR3ko (blacksquare, square, filled) mice. Two-way analysis of variance (ANOVA) shows significance at P < 0.02 (*). One representative experiment of three is shown. (B-E) Representative images from DR3wt (B) and DR3ko (C) mice, 3 d after arthritis induction, and DR3wt (D) and DR3ko (E) mice, 21 d after arthritis induction. Bars, 200 mum. Inflammatory tissue (black arrowheads) and erosions (blue arrowheads) are shown. (F) Breakdown of each component of the AI. *, P < 0.05; **, P < 0.01. (G) AI scores from DR3wt and DR3ko mice. **, P < 0.01. Lines mark means of graphed points. (H and I) Representative images of collagen around knee joints from DR3wt (H) and DR3ko (I) mice. Sections were stained with Safranin O/Fast Green to visualize collagen in red. Tidemark of cartilage depletion (arrows) is shown. Bars, 50 mum. (J) Estimated cartilage depletion from DR3wt and DR3ko mice. *, P < 0.05. Each point in the summary graphs represents a single 6 DR3wt (triangle up) or DR3ko (blacksquare, square, filled) animal.
###end p 11
###begin p 12
###xml 119 121 119 121 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ko</sup>
###xml 461 463 454 456 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib21">21</xref>
###xml 678 680 671 673 <sup xmlns:xlink="http://www.w3.org/1999/xlink">wt</sup>
###xml 682 690 675 683 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1 B</xref>
###xml 699 701 692 694 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ko</sup>
###xml 708 716 701 709 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1 C</xref>
###xml 768 770 761 763 <sup xmlns:xlink="http://www.w3.org/1999/xlink">wt</sup>
###xml 920 928 913 921 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1 D</xref>
###xml 947 949 940 942 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ko</sup>
###xml 1114 1122 1107 1115 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1 E</xref>
###xml 1205 1207 1198 1200 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ko</sup>
###xml 1225 1227 1218 1220 <sup xmlns:xlink="http://www.w3.org/1999/xlink">wt</sup>
###xml 1234 1242 1227 1235 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1 F</xref>
###xml 1301 1309 1294 1302 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1 G</xref>
###xml 122 126 <span type="species:ncbi:10090">mice</span>
###xml 702 706 <span type="species:ncbi:10090">mice</span>
###xml 771 775 <span type="species:ncbi:10090">mice</span>
###xml 950 954 <span type="species:ncbi:10090">mice</span>
###xml 1228 1232 <span type="species:ncbi:10090">mice</span>
We next assessed whether more rapid resolution of joint swelling was translated to improved pathological outcome in DR3ko mice. Examination of histopathological severity was performed on joint sections taken during the acute inflammatory phase when TNFalpha, IL-1beta, and IL-6 reach a peak and destructive pathology first becomes detectable (3 d after induction) and when there is maximal evidence of structural damage within the joint (21 d after induction) (21). The severity of arthritis (arthritis index [AI]) was quantified in hematoxylin and eosin (H&E)-stained sections by grading parameters as described in Materials and methods. On day 3 after arthritis induction, DR3wt (Fig. 1 B) and DR3ko mice (Fig. 1 C) did not differ histopathologically. By day 21, DR3wt mice had developed arthritis characterized by extensive cellular infiltration, synovial hyperplasia, formation of a thick pannus, and bone erosions (Fig. 1 D). In contrast, DR3ko mice displayed mild pathological features of arthritis, showing general absence of synovial hyperplasia, lack of pannus formation, and no evidence of bone erosion (Fig. 1 E). Indeed, all scoring parameters were either absent or significantly milder in DR3ko compared with DR3wt mice (Fig. 1 F). This translated into a significant reduction in the AI (Fig. 1 G).
###end p 12
###begin p 13
###xml 218 220 218 220 <sup xmlns:xlink="http://www.w3.org/1999/xlink">wt</sup>
###xml 344 352 344 352 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1 H</xref>
###xml 358 360 358 360 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ko</sup>
###xml 408 416 408 416 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1 I</xref>
###xml 638 640 638 640 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ko</sup>
###xml 221 225 <span type="species:ncbi:10090">mice</span>
###xml 361 365 <span type="species:ncbi:10090">mice</span>
###xml 641 645 <span type="species:ncbi:10090">mice</span>
As a second outcome measure of structural damage to the joint, we assessed proteoglycan depletion from articular cartilage on the femoral head using Safranin O/Fast Green staining 21 d after arthritis induction. In DR3wt mice, cartilage was severely depleted, as illustrated by lack of red Safranin O staining resulting in an obvious tidemark (Fig. 1 H). DR3ko mice did not display much cartilage depletion (Fig. 1 I), retaining similar levels of Safranin O staining as nonarthritic control left knees (not depicted). Collectively, this data indicate that there is considerable protection against degenerative AIA disease pathology in DR3ko mice.
###end p 13
###begin title 14
TL1A exacerbates disease in a DR3-dependent fashion
###end title 14
###begin p 15
###xml 148 151 148 151 <sup xmlns:xlink="http://www.w3.org/1999/xlink">het</sup>
###xml 224 226 224 226 <sup xmlns:xlink="http://www.w3.org/1999/xlink">wt</sup>
###xml 233 242 233 242 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Figs. 1 G</xref>
###xml 247 250 247 250 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">2 A</xref>
###xml 498 501 498 501 <sup xmlns:xlink="http://www.w3.org/1999/xlink">het</sup>
###xml 508 516 508 516 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2 A</xref>
###xml 690 705 690 705 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2, B and C</xref>
###xml 783 785 783 785 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ko</sup>
###xml 829 837 829 837 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2 D</xref>
###xml 868 870 868 870 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ko</sup>
###xml 949 964 949 964 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2, E and F</xref>
###xml 152 156 <span type="species:ncbi:10090">mice</span>
###xml 227 231 <span type="species:ncbi:10090">mice</span>
###xml 502 506 <span type="species:ncbi:10090">mice</span>
###xml 786 790 <span type="species:ncbi:10090">mice</span>
###xml 871 875 <span type="species:ncbi:10090">mice</span>
To confirm that resistance to AIA was DR3 specific, TL1A was injected with mBSA on day 0 of the AIA model at escalating quantities up to 100 ng. DR3het mice were chosen as they showed intermediate AI scores compared with DR3wt mice (Figs. 1 G and 2 A). Consequently, exacerbation or amelioration of disease after TL1A injection could be quantified, irrespective of the inherent variability in the model. Coadministration of TL1A resulted in significant dose-dependent exacerbation of disease in DR3het mice (Fig. 2 A). This was strikingly illustrated by the effect on size of bone erosions and severity of bone destruction, which increased in a dose-dependent fashion after TL1A injection (Fig. 2, B and C). In contrast, TL1A had no significant effect on arthritis progression in DR3ko mice over the concentration range studied (Fig. 2 D). Representative images of DR3ko mice receiving 1 and 100 ng TL1A show the continued absence of bone erosions (Fig. 2, E and F). TL1A therefore exacerbates AIA and, in particular, adverse bone pathology in a DR3-dependent manner.
###end p 15
###begin p 16
###xml 0 70 0 70 <bold xmlns:xlink="http://www.w3.org/1999/xlink">TL1A promotes adverse bone pathology of AIA in a DR3-dependent manner.</bold>
###xml 123 126 123 126 <sup xmlns:xlink="http://www.w3.org/1999/xlink">het</sup>
###xml 206 209 206 209 <sup xmlns:xlink="http://www.w3.org/1999/xlink">het</sup>
###xml 244 246 244 246 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ko</sup>
###xml 293 296 293 296 <sup xmlns:xlink="http://www.w3.org/1999/xlink">het</sup>
###xml 430 432 430 432 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ko</sup>
###xml 479 481 479 481 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ko</sup>
###xml 596 599 595 598 <sup xmlns:xlink="http://www.w3.org/1999/xlink">het</sup>
###xml 611 613 610 612 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ko</sup>
###xml 127 131 <span type="species:ncbi:10090">mice</span>
###xml 210 214 <span type="species:ncbi:10090">mice</span>
###xml 247 251 <span type="species:ncbi:10090">mice</span>
###xml 297 301 <span type="species:ncbi:10090">mice</span>
###xml 433 437 <span type="species:ncbi:10090">mice</span>
###xml 482 486 <span type="species:ncbi:10090">mice</span>
###xml 614 618 <span type="species:ncbi:10090">mice</span>
TL1A promotes adverse bone pathology of AIA in a DR3-dependent manner. (A) AI with increasing administration of TL1A in DR3het mice. Horizontal lines mark means of graphed points. Open symbols represent DR3het mice; filled symbols represent DR3ko mice. (B and C) Representative images from DR3het mice with no (B) or 100 ng (C) TL1A added. Bone erosions (arrowheads) are shown. (D) AI with increasing administration of TL1A to DR3ko mice. (E and F) Representative images from DR3ko mice with 1 (E) or 100 (F) ng TL1A added. Bars, 200 mum. One-way ANOVA showed significance of TL1A addition to DR3het but not DR3ko mice. *, P < 0.05. Each point in the summary graphs represents a single animal. One representative experiment of two is shown.
###end p 16
###begin title 17
DR3 expression promotes osteoclastogenesis in AIA
###end title 17
###begin p 18
###xml 11 13 11 13 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ko</sup>
###xml 355 357 355 357 <sup xmlns:xlink="http://www.w3.org/1999/xlink">wt</sup>
###xml 365 367 365 367 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ko</sup>
###xml 409 420 409 420 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3, A&#8211;C</xref>
###xml 636 638 636 638 <sup xmlns:xlink="http://www.w3.org/1999/xlink">wt</sup>
###xml 675 677 675 677 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ko</sup>
###xml 684 695 684 695 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3, D&#8211;F</xref>
###xml 14 18 <span type="species:ncbi:10090">mice</span>
###xml 368 372 <span type="species:ncbi:10090">mice</span>
###xml 639 643 <span type="species:ncbi:10090">mice</span>
###xml 678 682 <span type="species:ncbi:10090">mice</span>
Because DR3ko mice were protected from the development of subchondral bone erosions in AIA, we elected to quantify the number of bone-resorbing osteoclasts within the joint at two distinct sites of epiphyseal bone. Osteoclasts are clearly visualized as large red multinucleated cells with tartrate-resistant acid phosphatase (TRAP). TRAP expression in DR3wt and DR3ko mice was comparable in the femoral head (Fig. 3, A-C) and growth plate (not depicted). However, in the periosteum at areas adjacent to pannus formation, where focal bone erosions could be visualized at high magnification, TRAP staining was significantly greater in DR3wt mice than at equivalent areas in DR3ko mice (Fig. 3, D-F). These data implicate a role for DR3 in generation of osteoclasts at sites of bone pathology but not in influencing osteoclastogenesis in areas away from the pannus.
###end p 18
###begin p 19
###xml 42 44 42 44 <sup xmlns:xlink="http://www.w3.org/1999/xlink">wt</sup>
###xml 52 54 52 54 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ko</sup>
###xml 0 60 0 60 <bold xmlns:xlink="http://www.w3.org/1999/xlink">TRAP and F4/80 expression in joints of DR3<sup>wt</sup> and DR3<sup>ko</sup> mice.</bold>
###xml 280 282 280 282 <sup xmlns:xlink="http://www.w3.org/1999/xlink">wt</sup>
###xml 294 296 294 296 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ko</sup>
###xml 315 316 315 316 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 523 525 523 525 <sup xmlns:xlink="http://www.w3.org/1999/xlink">wt</sup>
###xml 564 566 564 566 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ko</sup>
###xml 585 586 585 586 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 615 617 615 617 <italic xmlns:xlink="http://www.w3.org/1999/xlink">js</italic>
###xml 632 633 632 633 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 643 644 643 644 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c</italic>
###xml 664 666 664 666 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ko</sup>
###xml 703 704 703 704 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 731 733 731 733 <sup xmlns:xlink="http://www.w3.org/1999/xlink">wt</sup>
###xml 811 813 811 813 <sup xmlns:xlink="http://www.w3.org/1999/xlink">wt</sup>
###xml 825 827 825 827 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ko</sup>
###xml 954 956 954 956 <sup xmlns:xlink="http://www.w3.org/1999/xlink">wt</sup>
###xml 968 970 968 970 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ko</sup>
###xml 1141 1143 1141 1143 <sup xmlns:xlink="http://www.w3.org/1999/xlink">wt</sup>
###xml 1164 1166 1154 1156 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ko</sup>
###xml 55 59 <span type="species:ncbi:10090">mice</span>
###xml 301 305 <span type="species:ncbi:10090">mice</span>
###xml 526 530 <span type="species:ncbi:10090">mice</span>
###xml 567 571 <span type="species:ncbi:10090">mice</span>
###xml 667 671 <span type="species:ncbi:10090">mice</span>
###xml 734 738 <span type="species:ncbi:10090">mice</span>
###xml 832 836 <span type="species:ncbi:10090">mice</span>
###xml 975 979 <span type="species:ncbi:10090">mice</span>
TRAP and F4/80 expression in joints of DR3wt and DR3ko mice. Sections were stained for TRAP or F4/80 as described in Materials and methods. Horizontal lines mark means of graphed points. (A and B) Representative images of TRAP staining at day 21 after arthritic induction from DR3wt (A) and DR3ko (B) mice. Red TRAP+ staining (arrows) is shown. (C) Summary of TRAP staining in femoral head at day 21. (D and E) Representative images of TRAP staining around areas of bone erosion at day 21 after arthritic induction from DR3wt mice (D) and equivalent areas from DR3ko mice (E). Red TRAP+ staining (arrows) is shown; js, joint space; p, pannus; c, cartilage. (F) DR3ko mice show significantly reduced TRAP+ staining compared with DR3wt mice. *, P < 0.05. (G and H) Representative images of F4/80 staining from DR3wt (G) and DR3ko (H) mice, 3 d after arthritis induction. (I) Summary of day-3 data. (J and K) Representative images of F4/80 staining from DR3wt (J) and DR3ko (K) mice, 21 d after induction of arthritis. F4/80-positive cells (arrows) are shown. (L) Summary of day-21 data. Each point in the summary graphs represents a single DR3wt (triangle up) or DR3ko (blacksquare, square, filled) animal. Bars, 50 mum. One representative experiment of two is shown.
###end p 19
###begin title 20
###xml 3 5 3 5 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ko</sup>
###xml 6 10 <span type="species:ncbi:10090">mice</span>
DR3ko mice show normal myeloid infiltration within joints in AIA
###end title 20
###begin p 21
###xml 563 565 563 565 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ko</sup>
###xml 573 575 573 575 <sup xmlns:xlink="http://www.w3.org/1999/xlink">wt</sup>
###xml 753 755 753 755 <sup xmlns:xlink="http://www.w3.org/1999/xlink">wt</sup>
###xml 763 765 763 765 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ko</sup>
###xml 772 783 772 783 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3, G&#8211;I</xref>
###xml 902 904 902 904 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ko</sup>
###xml 912 914 912 914 <sup xmlns:xlink="http://www.w3.org/1999/xlink">wt</sup>
###xml 944 945 944 945 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1018 1020 1018 1020 <sup xmlns:xlink="http://www.w3.org/1999/xlink">wt</sup>
###xml 1028 1030 1028 1030 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ko</sup>
###xml 1037 1048 1037 1048 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3, J&#8211;L</xref>
###xml 1342 1344 1342 1344 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ko</sup>
###xml 186 193 <span type="species:ncbi:9606">patient</span>
###xml 353 358 <span type="species:ncbi:9606">human</span>
###xml 576 580 <span type="species:ncbi:10090">mice</span>
###xml 766 770 <span type="species:ncbi:10090">mice</span>
###xml 915 919 <span type="species:ncbi:10090">mice</span>
###xml 1031 1035 <span type="species:ncbi:10090">mice</span>
###xml 1345 1349 <span type="species:ncbi:10090">mice</span>
Recruitment of mononuclear cells to the subintimal synovial lining layer and to periarticular adipose tissue adjacent to the meniscus is a process characteristic of the AIA model and RA patient joints. Indeed, the degree of macrophage (osteoclast precursor) infiltration within rheumatoid joint has been correlated with severity of structural damage in human disease. To assess whether reduction in osteoclast number was caused by impaired recruitment of these cells to the joint, we performed immunohistochemical analysis of F4/80 expression in sections from DR3ko and DR3wt mice on days 3 and 21 after arthritis induction. On day 3, some F4/80 expression was detected in the periarticular adipose tissue, which did not differ significantly between DR3wt and DR3ko mice (Fig. 3, G-I). By day 21, F4/80 staining was markedly increased with strong F4/80 expression visualized microscopically in both DR3ko and DR3wt mice. Quantification of F4/80+ cells again revealed no significant difference in expression between DR3wt and DR3ko mice (Fig. 3, J-L). Overall, these data suggest that absence of DR3 does not impair recruitment of myeloid cells to the joint, nor does it affect overall numbers of basal mature osteoclasts in the femoral head. Neither hypothesis can explain the reduction in osteoclast numbers in areas of bone pathology in DR3ko mice.
###end p 21
###begin title 22
TL1A promotes osteoclastogenesis in vitro in a DR3-dependent fashion
###end title 22
###begin p 23
###xml 234 236 234 236 <sup xmlns:xlink="http://www.w3.org/1999/xlink">wt</sup>
###xml 273 281 273 281 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4 A</xref>
###xml 296 298 296 298 <sup xmlns:xlink="http://www.w3.org/1999/xlink">wt</sup>
###xml 306 308 306 308 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ko</sup>
###xml 465 466 465 466 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 474 482 474 482 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4 B</xref>
###xml 566 568 566 568 <sup xmlns:xlink="http://www.w3.org/1999/xlink">wt</sup>
###xml 580 582 580 582 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ko</sup>
###xml 588 599 588 599 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4, B&#8211;D</xref>
###xml 674 682 674 682 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4 E</xref>
###xml 829 837 829 837 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4 F</xref>
###xml 1194 1202 1194 1202 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4 G</xref>
###xml 237 241 <span type="species:ncbi:10090">mice</span>
###xml 309 313 <span type="species:ncbi:10090">mice</span>
###xml 1020 1026 <span type="species:ncbi:10090">murine</span>
###xml 1087 1093 <span type="species:ncbi:9606">humans</span>
###xml 1170 1175 <span type="species:ncbi:9606">human</span>
We therefore tested the possibility that TL1A could directly promote differentiation of osteoclasts. To achieve this, we used an in vitro system of osteoclastogenesis from adherent BM-derived cells (BMC). BM macrophages (BMM) from DR3wt mice were confirmed to express DR3 (Fig. 4 A). BMC from DR3wt and DR3ko mice did not differ in their ability to generate osteoclasts in the presence of soluble RANK-L and M-CSF as measured by the formation of multinucleated TRAP+ cells (Fig. 4 B). However, TL1A addition significantly enhanced development of osteoclasts from DR3wt but not DR3ko BMC (Fig. 4, B-D). TL1A in the absence of RANK-L and M-CSF could not generate osteoclasts (Fig. 4 E). The functional capacity of in vitro-generated osteoclasts to destroy bone was visualized by toluidine blue staining of pits in the ivory discs (Fig. 4 F). This data indicates that TL1A is not necessary for osteoclastogenesis per se, but promotes it in the presence of RANK-L and M-CSF and in a DR3-dependent fashion. In support of our murine data and highlighting the significance of these results for humans, TL1A significantly promoted osteoclastogenesis from monocytes derived from human peripheral blood (Fig. 4 G).
###end p 23
###begin p 24
###xml 0 56 0 56 <bold xmlns:xlink="http://www.w3.org/1999/xlink">TL1A promotes DR3-dependent in vitro osteoclastogenesis.</bold>
###xml 237 238 237 238 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 416 418 416 418 <sup xmlns:xlink="http://www.w3.org/1999/xlink">wt</sup>
###xml 440 442 440 442 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ko</sup>
###xml 648 650 648 650 <sup xmlns:xlink="http://www.w3.org/1999/xlink">wt</sup>
###xml 460 464 <span type="species:ncbi:10090">mice</span>
###xml 487 491 <span type="species:ncbi:10090">mice</span>
###xml 651 655 <span type="species:ncbi:10090">mice</span>
###xml 949 954 <span type="species:ncbi:9606">human</span>
TL1A promotes DR3-dependent in vitro osteoclastogenesis. (A) RT-PCR of DR3 in BMM. In vitro osteoclastogenesis assays were performed as described in Materials and methods. Osteoclast numbers were estimated by counting multinucleated TRAP+ cells. (B) Effect of TL1A on proportion of osteoclasts generated in presence of RANKL and M-CSF. *, P = 0.0003. Each point represents a single ivory disc from experiments on DR3wt (open symbols) or DR3ko (filled symbols) mice. Four discs from four mice were counted for each treatment. Lines mark means of graphed points. One representative experiment of two is shown. (C-E) TRAP staining of BM cells from DR3wt mice on discs with RANK-L + M-CSF and no TL1A (C) or 10 ng/ml TL1A (D) and TL1A (E), but no RANKL and M-CSF. Bars, 50 mum. (F) Toluidine blue staining of ivory discs showing pit-forming ability of osteoclasts generated in vitro. Bar, 150 mum. (G) Effect of TL1A on osteoclastogenesis from adherent human peripheral blood mononuclear cells and proportion of osteoclasts in cultures shown with (triangle down) or without (black triangle) exogenous TL1A added. **, P = 0.0013. One representative experiment of two is shown.
###end p 24
###begin title 25
Anti-TL1A neutralizing antibody ameliorates AIA and CIA
###end title 25
###begin p 26
###xml 123 138 123 138 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5, A and B</xref>
###xml 437 439 437 439 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ko</sup>
###xml 446 454 446 454 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5 C</xref>
###xml 536 544 536 544 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5 D</xref>
###xml 812 820 812 820 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5 E</xref>
###xml 972 980 972 980 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5 F</xref>
###xml 1062 1070 1062 1070 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5 G</xref>
###xml 1161 1169 1161 1169 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5 H</xref>
###xml 1245 1247 1245 1247 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ko</sup>
###xml 99 102 <span type="species:ncbi:10116">rat</span>
###xml 110 116 <span type="species:ncbi:10090">murine</span>
###xml 440 444 <span type="species:ncbi:10090">mice</span>
###xml 520 524 <span type="species:ncbi:10090">mice</span>
###xml 706 710 <span type="species:ncbi:10090">mice</span>
###xml 765 769 <span type="species:ncbi:10090">mice</span>
###xml 865 869 <span type="species:ncbi:10090">mice</span>
###xml 1016 1020 <span type="species:ncbi:10090">mice</span>
###xml 1101 1105 <span type="species:ncbi:10090">mice</span>
###xml 1248 1252 <span type="species:ncbi:10090">mice</span>
###xml 1335 1338 <span type="species:ncbi:9606">man</span>
To test the therapeutic potential of countering the DR3-TL1A pathway, we generated an antagonistic rat mAb to murine TL1A (Fig. 5, A and B) and applied it in AIA and the systemic model of disease. CIA is the industry standard for testing potential therapeutic agents against RA. A single treatment of anti-TL1A at the point of arthritic induction in AIA resulted in more rapid resolution of swelling that mirrored our observations in DR3ko mice (Fig. 5 C). In CIA, clinical signs of arthritis became apparent in control mice on day 25 (Fig. 5 D). Disease activity was assessed by assigning scores to each paw according to degree of redness, swelling, and joint involvement. Paw scores in anti-TL1A-treated mice were consistently lower than in control IgG2a-treated mice, reaching significance on days 27 and 28 (Fig. 5 E). Disease activity in control IgG2a-treated mice was characterized by leukocyte infiltration of synovial tissues and variable degrees of bone erosion (Fig. 5 F). Specimens from anti-TL1A-treated mice demonstrated mild changes by comparison (Fig. 5 G). The AI in anti-TL1A-treated mice was significantly less than in IgG2a-treated controls (Fig. 5 H). These data are consistent with the protection against AIA observed in DR3ko mice and suggest that countering the DR3-TL1A pathway may be therapeutic against RA in man.
###end p 26
###begin p 27
###xml 0 88 0 88 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Early therapeutic intervention with anti-TL1A antibody arrests development of arthritis.</bold>
###xml 1236 1237 1207 1208 <italic xmlns:xlink="http://www.w3.org/1999/xlink">i</italic>
###xml 1270 1271 1241 1242 <italic xmlns:xlink="http://www.w3.org/1999/xlink">e</italic>
###xml 104 107 <span type="species:ncbi:10116">rat</span>
###xml 625 629 <span type="species:ncbi:10090">mice</span>
###xml 871 875 <span type="species:ncbi:10090">mice</span>
###xml 1378 1382 <span type="species:ncbi:10090">mice</span>
Early therapeutic intervention with anti-TL1A antibody arrests development of arthritis. (A) Binding of rat anti-TL1A mAb (TAN 2-2) to J558L cells transfected with plasmid encoding membrane-bound TL1A. Shaded histogram and dotted line represent binding of isotype control and TAN 2-2 to plasmid only transfected cells, respectively. Binding of isotype control and TAN 2-2 to TL1A-expressing cells is represented by a thin and thick line, respectively. (B) Titration of TAN 2-2 binding to J558L cells expressing membrane-bound TL1A. (C) Time course of swelling in AIA after anti-TL1A mAb treatment. Data are mean +/- SEM from mice treated with control IgG2A (black triangle) or anti-TL1A (triangle down) mAb. One representative experiment of two is shown. *, P < 0.02 by two-way ANOVA. CIA was induced as described in Materials and methods. All data were derived from six mice for each treatment. (D) Arthritis incidence tabulated over 28-d time course. (E) Arthritis severity as a mean paw score from day 20 when dosing schedule for anti-TL1A and control IgG2a was started. Data are mean +/- SEM. Timing of injections are shown (arrows). (F and G) Representative images of H&E-stained sections from control IgG2a (F) and anti-TL1A (G). i, intense synovial infiltration; e, aggressive bone erosion. Bars, 200 mum. (H) Analysis of AI of CIA in control IgG2a and anti-TL1A-treated mice. Dotted horizontal line depicts mean for each group. *, P < 0.05; **, P = 0.01; ***, P = 0.006.
###end p 27
###begin title 28
The role of the DR3-TL1A axis in driving adverse bone pathology in inflammatory arthritis
###end title 28
###begin p 29
###xml 26 28 26 28 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ko</sup>
###xml 214 216 214 216 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ko</sup>
###xml 457 459 457 459 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ko</sup>
###xml 535 537 535 537 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ko</sup>
###xml 810 812 810 812 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ko</sup>
###xml 886 887 886 887 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 929 931 929 931 <sup xmlns:xlink="http://www.w3.org/1999/xlink">wt</sup>
###xml 939 941 939 941 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ko</sup>
###xml 1371 1373 1371 1373 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ko</sup>
###xml 1876 1878 1876 1878 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib22">22</xref>
###xml 1987 1989 1987 1989 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib18">18</xref>
###xml 2035 2037 2035 2037 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib11">11</xref>
###xml 29 33 <span type="species:ncbi:10090">mice</span>
###xml 217 221 <span type="species:ncbi:10090">mice</span>
###xml 460 464 <span type="species:ncbi:10090">mice</span>
###xml 538 542 <span type="species:ncbi:10090">mice</span>
###xml 813 817 <span type="species:ncbi:10090">mice</span>
###xml 942 946 <span type="species:ncbi:10090">mice</span>
###xml 1374 1378 <span type="species:ncbi:10090">mice</span>
###xml 1960 1966 <span type="species:ncbi:10090">murine</span>
###xml 1974 1980 <span type="species:ncbi:10090">murine</span>
###xml 2000 2005 <span type="species:ncbi:9606">human</span>
###xml 2042 2047 <span type="species:ncbi:10090">mouse</span>
Our findings show that DR3ko mice are resistant to the adverse joint pathology that is typical in AIA and are consistent with an essential role for the DR3-TL1A pathway in development of inflammatory arthritis. DR3ko mice elicited an initial inflammatory reaction in response to AIA induction, such that at day 3 after arthritis induction, there was no difference in histopathological scoring or level of inflammatory cell infiltrate between control and DR3ko mice. Resolution of inflammation, however, occurred at a faster rate in DR3ko mice, as indicated by reduction in joint swelling over the course of the study and reduction in all histopathological parameters measured at day 21 after arthritic induction. Of particular note was the absence of bone erosion and marked reduction in cell infiltrate in DR3ko mice in later stages of disease. Comparable numbers of infiltrating F4/80+ macrophages were present in joints of DR3wt and DR3ko mice, despite the observed differences in joint pathology. Therefore, the mechanisms involved in initiating the inflammatory reaction and in recruitment of myeloid cells into the joint appear intact in the absence of DR3. Because of this, we chose to investigate differentiation of osteoclasts, discovering that osteoclast differentiation in vitro and bone erosion in vivo was exacerbated by exogenous TL1A in control but not DR3ko mice. These DR3-dependent effects confirm that TL1A is a specific functional ligand for DR3 and identifies the control of osteoclasts as a novel function for DR3. The potential of countering the DR3-TL1A pathway as a therapy was proven by amelioration of CIA and AIA using a neutralizing anti-TL1A mAb. Interestingly, anti-TL1A therapy was not totally protective. The possibility remains that there may be secondary ligands for DR3 and TL1A as implicated for TL1A by recent data in renal inflammation (22), but detailed studies have shown no other TNFSF/TNFRSF family members that bind murine DR3 or murine TL1A (18), whereas human TL1A binds Decoy Receptor 3 (11), a mouse homologue of which has not been found.
###end p 29
###begin p 30
###xml 329 331 325 327 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib23">23</xref>
###xml 476 478 468 470 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib20">20</xref>
###xml 631 633 619 621 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib24">24</xref>
###xml 699 701 687 689 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib20">20</xref>
###xml 914 916 902 904 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib20">20</xref>
###xml 1018 1026 1006 1014 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2 A</xref>
###xml 1457 1459 1445 1447 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib25">25</xref>
###xml 2113 2115 2101 2103 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ko</sup>
###xml 574 579 <span type="species:ncbi:9606">human</span>
###xml 1312 1317 <span type="species:ncbi:9606">human</span>
###xml 2116 2120 <span type="species:ncbi:10090">mice</span>
This is the first paper reporting that signaling through DR3 on myeloid cells promotes osteoclastogenesis, although it is clear from our data that it is not a prerequisite for, nor can it induce, this differentiation in the absence of RANK-L and M-CSF. In this respect, it mirrors functions that have been reported for TNFalpha (23). However, a function independent of TNFalpha is suggested by a recent paper showing that macrophages produce TL1A independent of TNF activity (20). TL1A expression, including release of active soluble forms of the protein, can be induced on human monocytes by FcgammaR stimulation through soluble (24) and insoluble immune complexes purified from RA synovial fluid (20). The majority of stromal macrophages in RA synovial tissue express TL1A, and in vitro stimulation of monocytes with PEG precipitates from RA samples results in production of nanogram quantities of soluble TL1A (20). This suggests very high levels in localized RA joint akin to the levels we used to exacerbate AIA (Fig. 2 A). The implication is that in inflammatory arthritis, myeloid cells may exhibit a positive feedback loop whereby TL1A is triggered through ICs and can drive differentiation of bone-destroying cells if the right cytokine milieu is provided. Intriguingly, TL1A also has varied effects on human osteoblast cell lines in vitro, inhibiting differentiation and promoting quiescence at low densities but inducing death at high densities (25). We therefore propose that the DR3-TL1A pathway may act as a switch that is capable of directly activating osteoclast but also inhibiting osteoblast differentiation and, in so doing, disregulate the homeostatic balance of degradation and formation in normal bone into the detrimental situation observed in destructive bone pathologies such as RA. Although our in vitro data supports this proposal, some caution is necessary in interpreting the contribution of direct TL1A-driven osteoclastogenesis to arthritic bone damage in vivo, as inflammation and bone erosion cannot be dissociated in AIA or CIA. The possibility remains that the resistance of DR3ko mice to bone erosion is secondary to DR3-TL1A-dependent control of other parts of the inflammatory process.
###end p 30
###begin p 31
###xml 92 94 92 94 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ko</sup>
###xml 101 107 101 107 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1</xref>
###xml 367 369 367 369 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib17">17</xref>
###xml 433 435 433 435 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib26">26</xref>
###xml 584 586 584 586 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib11">11</xref>
###xml 668 670 664 666 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib15">15</xref>
###xml 672 674 668 670 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib27">27</xref>
###xml 676 678 672 674 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib28">28</xref>
###xml 732 734 728 730 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib14">14</xref>
###xml 749 751 745 747 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib13">13</xref>
###xml 814 816 810 812 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib12">12</xref>
###xml 818 820 814 816 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib16">16</xref>
###xml 893 895 889 891 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib29">29</xref>
###xml 1004 1006 1000 1002 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib27">27</xref>
###xml 1256 1258 1252 1254 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ko</sup>
###xml 1338 1340 1334 1336 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ko</sup>
###xml 95 99 <span type="species:ncbi:10090">mice</span>
###xml 260 265 <span type="species:ncbi:9606">human</span>
###xml 1259 1263 <span type="species:ncbi:10090">mice</span>
In this respect, our data also show that cartilage depletion is significantly reduced in DR3ko mice (Fig. 1). Cartilage depletion is attributed to the effects of matrix metalloproteinases (MMPs), levels of which are raised in RA joint. In vitro experiments on human cell lines have shown that DR3 activation can induce the production of MMP-1, -9, and -13 in THP-1s (17). These MMPs have all been associated with RA joint pathology (26). In addition, it is also established that TL1A plays an important role in T cell function. TL1A has been shown to costimulate IL-2 responsiveness (11) and synergize with the TCR and IL-12/IL-18 pathways to induce IFNgamma release (15, 27, 28). TL1A also amplifies cytokine release by NKT cells (14) and T cells (13) and regulates the development of proinflammatory Th17 cells (12, 16), which are reported to aid osteoclastogenesis in autoimmune arthritis (29). The action of TL1A on T cells may also be regulated by differential expression of splice variants of DR3 (27). The exact role of TL1A and DR3 on lymphocytes in inflammatory arthritis remains to be elucidated, but it is interesting to note that we find normal anti-mBSA Ab levels in serum, unchanged T cell proliferation to mBSA in draining lymph nodes of DR3ko mice after AIA induction, and normal in vitro generation of Th17 cells from DR3ko splenocytes (unpublished data).
###end p 31
###begin p 32
###xml 57 59 57 59 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ko</sup>
###xml 60 64 <span type="species:ncbi:10090">mice</span>
In summary, we have induced inflammatory arthritis in DR3ko mice and found that they exhibit strong resistance to the adverse pathology observed in AIA. We show DR3-dependent TL1A-driven exacerbation of bone damage in vivo and promotion of osteoclastogenesis in vitro. We also show that anti-TL1A therapy ameliorates disease. Our data suggest that the DR3-TL1A pathway is an important component of inflammatory responses in joint disease and, as such, identifies a potential therapeutic target for treatment of diseases like RA but with potential impact in other diseases involving disrupted bone physiology.
###end p 32
###begin title 33
MATERIALS AND METHODS
###end title 33
###begin title 34
Animals.
###end title 34
###begin p 35
###xml 133 135 133 135 <sup xmlns:xlink="http://www.w3.org/1999/xlink">wt</sup>
###xml 155 158 155 158 <sup xmlns:xlink="http://www.w3.org/1999/xlink">het</sup>
###xml 172 174 172 174 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ko</sup>
###xml 220 222 220 222 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib10">10</xref>
###xml 8 13 <span type="species:ncbi:10090">mouse</span>
###xml 176 180 <span type="species:ncbi:10090">mice</span>
###xml 232 236 <span type="species:ncbi:10090">mice</span>
The DR3 mouse colony was founded from animals supplied by Cancer Research UK, London. All experiments were undertaken in male WT (DR3wt), heterozygous (DR3het), and KO (DR3ko) mice, which have been described previously (10). DBA/1J mice were acquired from Harlan, UK. Animals were used at 6-8 wk of age. All procedures were approved by the Local Research Ethics Committee and performed in strict accordance with Home Office-approved licenses PPL 30/1999 and 30/2361.
###end p 35
###begin title 36
###xml 13 19 <span type="species:ncbi:10090">murine</span>
Induction of murine AIA.
###end title 36
###begin p 37
###xml 41 43 41 43 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib30">30</xref>
###xml 218 238 217 237 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Bordetella pertussis</italic>
###xml 56 60 <span type="species:ncbi:10090">mice</span>
###xml 153 156 <span type="species:ncbi:31658">CFA</span>
###xml 218 238 <span type="species:ncbi:520">Bordetella pertussis</span>
AIA was induced as previously described (30). In brief, mice were s.c. immunized on two occasions, 1 wk apart, with 1 mg/ml mBSA with an equal volume of CFA. An additional i.p. injection of 100 mul of heat-inactivated Bordetella pertussis toxin was administered with the first immunization. AIA was induced in the hind right knee joint via an intraarticular injection of 10 mg/ml mBSA (6 mul), administered 21 d after the initial immunization. To assess the effect of TL1A or anti-TL1A administration, AIA was induced via mBSA injection in conjunction with 1, 10, or 100 ng of soluble TL1A (R&D Systems) or 100 ng of anti-TL1A mAb.
###end p 37
###begin title 38
###xml 16 19 <span type="species:ncbi:10116">rat</span>
###xml 25 30 <span type="species:ncbi:10090">mouse</span>
Generation of a rat anti-mouse TL1A monoclonal antibody.
###end title 38
###begin p 39
###xml 0 4 <span type="species:ncbi:10116">Rats</span>
###xml 76 81 <span type="species:ncbi:9606">human</span>
###xml 192 197 <span type="species:ncbi:10090">mouse</span>
###xml 243 258 <span type="species:ncbi:10029">Chinese hamster</span>
###xml 335 340 <span type="species:ncbi:9606">human</span>
###xml 621 626 <span type="species:ncbi:10090">mouse</span>
Rats were immunized with a soluble recombinant TL1A protein consisting of a human IgG1 Fc domain, with an additional hinge-like region at the C terminus, linked to the extracellular domain of mouse TL1A (T77-L252). The protein was produced in Chinese hamster ovary cells and was purified by immunoaffinity chromatography using an anti-human Fc mAb. Anti-TL1A mAb was generated by standard hybridoma technology and hybridoma supernatants were screened for binding to recombinant soluble and membrane-expressed TL1A. To generate cells expressing membrane-anchored TL1A, PCR fragments encoding the entire coding sequence of mouse TL1A were cloned into the mammalian expression vectors pEF1/V5-His A and pcDNA3.1 (Invitrogen), and plasmids were then transfected into J558L or 293T cells. Stable J558L cell lines expressing membrane-anchored TL1A were selected in Geneticin (400 mug/ml)-containing media. Splenic cDNA or IMAGE clone 30740802 was used as a template for PCR reactions to generate TL1A-encoding DNA fragments. Further selection of neutralizing anti-TL1A mAbs was based on the ability to block binding of soluble recombinant TL1A-Fc to anti-CD3/CD28-stimulated T cells.
###end p 39
###begin title 40
Anti-TL1A therapy in CIA.
###end title 40
###begin p 41
###xml 41 43 41 43 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib31">31</xref>
###xml 67 74 <span type="species:ncbi:9031">chicken</span>
###xml 312 316 <span type="species:ncbi:10090">mice</span>
###xml 370 375 <span type="species:ncbi:10090">mouse</span>
###xml 467 471 <span type="species:ncbi:10090">Mice</span>
###xml 652 655 <span type="species:ncbi:10116">rat</span>
###xml 989 993 <span type="species:ncbi:10090">mice</span>
###xml 1025 1029 <span type="species:ncbi:10090">mice</span>
CIA was induced as previously described (31). In brief, 2 mg/ml of chicken type II collagen (CII; Sigma-Aldrich) was emulsified with an equal volume of complete Freund's adjuvant and 100 mul of collagen/adjuvant mixture injected intradermally into several sites near the base of the tail of 7-wk-old male DBA/1J mice. A second identical booster was administered to each mouse 21 d after the first injection. The day of the first immunization was designated as day 0. Mice were randomly assigned to one of three treatment groups on day 20. Animals received nine daily 100-mul injections containing either 2.5 mg/kg of anti-TL1A or LEAF purified control rat IgG2a (Cambridge Biosciences) dissolved in sterile PBS or PBS alone administered by the i.p. route from day 20. Thereafter, arthritis incidence and severity was assessed daily until termination on day 28 when the disease severity limits were attained in IgG2a and PBS controls. The incidence of CIA was assessed as the percentage of mice developing arthritis among all mice. The severity of arthritis in each paw (paw score) was evaluated by using an established in-house scoring system: 0, normal; 1, mild but definite swelling in the ankle or wrist joint or redness and swelling limited to individual digits regardless of the number of digits affected; 2, moderate swelling of ankle or wrist; 3, severe redness and swelling of the ankle or wrist and proximal phalangeal joints; and 4, maximally inflamed limb with involvement of multiple joints, no ankylosis.
###end p 41
###begin title 42
Assessment of arthritis.
###end title 42
###begin p 43
###xml 388 390 388 390 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib30">30</xref>
Joint swelling was assessed on days 1, 2, 3, 5, 7, 14, and 21 after arthritis induction by measuring the difference between hind right (AIA) and hind left (control) knee joint diameters using an analogue micrometer. Animals were killed on day 3 or 21 for assessment of inflammatory and pathological changes within the joint. Histological assessment was performed as previously described (30). All joints were fixed in neutral buffered formal saline and decalcified with 10% formic acid for 2 wk at 4degreesC before embedding in paraffin wax. Serial sections of 7-mum thickness were taken and stained routinely with H&E for analysis. Two blinded independent observers scored the sections for cellular infiltration (0-5), cellular exudate (0-3), synovial hyperplasia (0-3), and bone erosion (0-3), with 0 representing a normal joint. The sum of all parameters gave the AI. Sections were additionally stained with Safranin O and Fast Green to assess cartilage depletion.
###end p 43
###begin title 44
RT-PCR.
###end title 44
###begin p 45
###xml 44 46 44 46 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib32">32</xref>
BMM were generated as previously described (32). RNA was extracted from BMM cultures using RNeasy (QIAGEN) after manufacturer's instructions, whereas cDNA was generated and RT-PCR performed according to standard Invitrogen protocols. PCR primers were as follows: beta-actin, forward 5'-CGGCCAGGTCATCACTATTG-3' and reverse 5'-CTCAGTAACCCGCCTAG-3' giving a 410-bp product; and DR3, forward 5'-CTAAGGCTTGCACTGCTGTCT-3' and reverse 5'-GAGCATCTCATACTGCTGGTC-3' giving a 457-bp product. The PCR consisted of 33 cycles with a 59degreesC annealing temperature.
###end p 45
###begin title 46
TRAP staining for osteoclasts.
###end title 46
###begin p 47
For TRAP staining, joints were decalcified in EDTA (7%), rehydrated, and incubated with TRAP staining solution containing 0.1 M acetate buffer, 0.5 M sodium tartrate, 10 mg/ml naphthol AS-MX phosphate, 100 mul Triton X-100, and 0.3 mg/ml Fast Red Violet LB salt for 3 h at 37degreesC. Sections were then counterstained with hematoxylin before mounting in DPX. Images were captured using a digital camera (N457; Olympus), and TRAP-positive cells were analyzed using Photoshop CS3. 5 (Adobe). Randomly chosen selected areas were used for analysis.
###end p 47
###begin title 48
Immunohistochemistry for F4/80 expression.
###end title 48
###begin p 49
###xml 44 47 <span type="species:ncbi:10116">rat</span>
###xml 407 410 <span type="species:ncbi:10116">rat</span>
F4/80 expression was detected using an anti-rat HRP-DAB staining kit (R&D Systems) according to the manufacturer's instructions. In brief, sections were rehydrated and endogenous peroxidase activity was blocked. Antigen unmasking was achieved by incubating the sections in 0.1% prewarmed Trypsin/EDTA in PBS for 30 min at 37degreesC. After blocking steps, sections were incubated overnight with 4 mug/ml of rat anti-F4/80 antibody (Invitrogen) or isotype control diluted in PBS followed by secondary antibody as per the manufacturer's instructions. Positively labeled cells were visualized using a streptavidin-HRP conjugate and DAB chromogen. Sections were counterstained with hematoxylin, dehydrated, and mounted in DPX. Images were captured using a digital camera (N457), and F4/80 positive cells were analyzed using Photoshop. Randomly selected areas were used for analysis.
###end p 49
###begin title 50
In vitro osteoclastogenesis assays.
###end title 50
###begin p 51
###xml 35 37 35 37 <sup xmlns:xlink="http://www.w3.org/1999/xlink">wt</sup>
###xml 45 47 45 47 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ko</sup>
###xml 172 173 168 169 <sc xmlns:xlink="http://www.w3.org/1999/xlink">l</sc>
###xml 220 221 216 217 <sup xmlns:xlink="http://www.w3.org/1999/xlink">5</sup>
###xml 48 52 <span type="species:ncbi:10090">mice</span>
###xml 673 678 <span type="species:ncbi:9606">human</span>
BMC were removed from femurs of DR3wt and DR3ko mice by centrifugation after removal of the proximal end. BMC were resuspended in alpha-MEM supplemented with 10% FCS, 2 mM l-glutamine, and antibiotics (MEM-10) and 5 x 105 cells added to ivory discs. After 2 h at 37degreesC, nonadherent cells were removed by transfer of ivory discs to new wells with fresh media supplemented with 50 ng/ml RANKL and 25 ng/ml M-CSF with or without 10 ng/ml TL1A. All media were replenished after 3 d. TRAP staining was performed according to the manufacturer's instructions (Sigma-Aldrich) after 7 d. Six fields of view on each disc were counted for TRAP-positive multinucleated cells. For human osteoclastogenesis assays, peripheral blood mononuclear cells were used as a source for adherent cells and cultures were maintained for 21 d before TRAP staining.
###end p 51
###begin title 52
Statistical analysis.
###end title 52
###begin p 53
###xml 144 145 144 145 <italic xmlns:xlink="http://www.w3.org/1999/xlink">U</italic>
Readouts could not be assumed to be normally distributed as they were histological scores or percentages. Therefore, nonparametric Mann-Whitney U tests were used for statistical analysis. One-way unpaired and two-way ANOVAs were used when testing the influence of third parameters such as time or dose. Analyses were performed on GraphPad Prizm v4. P-values of </=0.05 were considered significant and values of </=0.01 were considered highly significant.
###end p 53
###begin p 54
This work was funded by the Medical Research Council, through a Medical Research Council Career Establishment Grant awarded to E.C.Y. Wang (G0300180), a Medical Research Council Collaboration Grant (G0500617), the Wellcome Trust and two PhD studentships, one part-funded by the I3-Interdisciplinary Research Group, Cardiff University.
###end p 54
###begin p 55
The authors have no conflicting financial interests.
###end p 55

